As Risperdal Lawsuits Move Forward, Missouri Federal Judge Remands Case Involving Generic Version to State Court, Bernstein Liebhard LLP Reports

Share Article

The Firm is representing numerous Risperdal lawsuit plaintiffs who allegedly developed gynecomastia (male breast growth) due to their use of the medication.

Free Case Review
Our Firm is representing numerous clients who allegedly developed gynecomastia due to their use of Risperdal. This risperidone case is of interest because it raises many of the same issues and involves some of the same Risperdal defendants.

As Risperdal lawsuits (http://www.risperdallawsuit2014.com/) continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that a federal judge in Missouri has remanded one case involving a generic version of the antipsychotic drug to state court. According to an Order dated December 4th, U.S. District Judge Charles A. Shaw of the Eastern District of Missouri ruled that the allegations put forth by a non-Missouri plaintiff were not fraudulently misjoined because they involved the same injuries and were “logically related” to the three other Missouri plaintiffs named in the risperidone lawsuit. Judge Shaw remanded the case back to St. Louis Circuit Court, where it was originally filed in June. (Morgan, et al. v. Janssen Pharmaceuticals Inc., et al., No. 4:14-1346)

“Our Firm is representing numerous clients who allegedly developed gynecomastia due to their use of Risperdal. This risperidone case is of interest because it raises many of the same issues and involves some of the same Risperdal defendants,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.

Risperdal Litigation
Risperdal, also sold generically as risperidone, is an atypical antipsychotic drug that is approved by the U.S. Food & Drug Administration (FDA) to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder. Recent research suggests that Risperdal is also prescribed for children with ADHD, although it has not been specifically cleared for this use by regulators.*

Court records indicate that more than 1,100 Risperdal lawsuits are now pending in a consolidated proceeding underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing claims. All of these cases were filed on behalf of individuals who allegedly suffered serious side effects related to its use, including gynecomastia. Among other things, these lawsuits accuse Janssen Pharmaceuticals and its parent company, Johnson & Johnson, of failing to provide adequate warnings regarding its association with male breast growth and other complications. The companies are also accused of improperly marketing Risperdal for off-label use in children. (In Re: Risperdal Litigation, Case Number 100300296).

Johnson & Johnson and Janssen were also accused of improperly marketing Risperdal and other drugs by the U.S. Department of Justice in a case that was settled last November. According to the Department of Justice, the $2.2 billion settlement was among the largest involving healthcare fraud in U.S. history. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Risperdal patients who allegedly developed gynecomastia due to their use of the medication may be entitled to seek compensation from Johnson & Johnson and Janssen Pharmaceuticals. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website